Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size

Clinical Cardiology

Volumn 35, Issue 6, 2012, Pages 359-364

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Maffioli, Pamela ^a   Mugellini, Amedeo ^a   Preti, Paola ^a   Perrone, Tiziano ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; TELMISARTAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART SIZE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE;

EID: 84862167277     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21994     Document Type: Article

References (35)

1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N. (Pubitemid 28507114)
2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
3. Fang MC, Go AS, Chang Y, et al ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810-815. (Pubitemid 351253746)
4. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-223. (Pubitemid 36204892)
5. Okin PM, Gerdts E, Wachtell K, et al. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens. 2010;28:1534-1540.
6. Allessie MA. Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol. 1998;9:1378-1393. (Pubitemid 28565136)
7. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008;51:1-11.
8. Raitt MH, Volgman AS, Zoble RG, et al AFFIRM Investigators. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2006;151:390-396. (Pubitemid 43148983)
9. Shin SH, Park MY, Oh WJ, et al. Left atrial volume is a predictor of atrial fibrillation recurrence after catheter ablation. J Am Soc Echocardiogr. 2008;21:697-702.
10. Toh N, Kanzaki H, Nakatani S, et al. Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of paroxysmal atrial fibrillation. Hypertension. 2010;55:1150-1156.
11. Marchese P, Bursi F, Delle Donne G, et al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr. 2011;12:214-221.
12. McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998;98:2765-2773. (Pubitemid 28564014)
13. Serra JL, Bendersky M. Atrial fibrillation and the reninangiotensin system. Ther Adv Cardiovasc Dis. 2008;2:215-223.
14. Von Lewinski D, Kockskämper J, Rübertus SU, et al. Direct proarrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail. 2008;10:1172-1176.
15. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26:2083-2092. (Pubitemid 41408600)
16. Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol. 2010;55:2299-2307.
17. Durin O, Pedrinazzi C, Inama G. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results. J Cardiovasc Med (Hagerstown). 2010;11:912-918.
18. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-336. (Pubitemid 34778957)
19. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur Heart J. 2003;24:2090-2098.
20. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27:1841-1846. (Pubitemid 44297391)
21. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47:46-50. (Pubitemid 44378223)
22. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21:1034-1039.
23. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther. 2012;17:34-43.
24. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120:85-91. (Pubitemid 47008995)
25. Disertori M, Latini R, Barlera S, et al GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-1617.
26. Goette A, Schön N, Kirchhof P, et al. Angiotensin II antagonist in paroxysmal atrial fibrillation: results from the ANTIPAF trial. Circ Arrhythm Electrophysiol. 2012;5:43-51.
27. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25:41-46. (Pubitemid 40571342)
28. Fogari R, Zoppi A, Ferrari I, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res. 2009;41:893-898.
29. Derosa G, Cicero AF, D'Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factoralpha. Hypertens Res. 2006;29:849-856. (Pubitemid 46062116)
30. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27:457-464. (Pubitemid 39157547)
31. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension. 2004;43:993-1002. (Pubitemid 38579904)
32. Yamagishi SI, Matsui T, Nakamura K. Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin-resistant patients. Horm Metab Res. 2008;40:640-644.
33. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 1997;96:1686-1695. (Pubitemid 27375370)
34. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation. 2003;108:668-671. (Pubitemid 36999249)
35. Abhayaratna WP, Seward JB, Appleton CP, et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol. 2006;47:2357-2363. (Pubitemid 43866385)